Autres langues Brii Biosciences Limited

Actions

2137

KYG1645A1094

Temps Différé Hong Kong S.E. Autres places de cotation 10:08:09 16/07/2024			Varia. 5j.	Varia. 1 janv.
1,07 ^HKD	+0,94 %		+8,08 %	-53,07 %

10/06	Brii Biosciences présente des données sur les médicaments contre l'hépatite B lors d'une conférence médicale européenne	MT
07/06	Brii Biosciences Limited annonce de nouvelles données provenant de deux études de phase 2 évaluant le BRII-179	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Brii Biosciences Presents Hepatitis B Drug Data at European Medical Conference	10/06
Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024	07/06
Brii Biosciences Limited Announces New Data from Two Phase 2 Studies Evaluating BRII-179	07/06
Brii Bio's Hepatitis B Drugs Get Breakthrough Therapy Designation in China	15/05
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies	14/05
Brii Biosciences Limited Announces Center for Drug Evaluation of the National Medical Products Administration of China Grants Breakthrough Therapy Designations for BRII-877 and BRII-835	14/05
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results	25/03
Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
Brii Biosciences Announces Agreements To Acquire VBI Vaccines' IP Rights In BRII-179	05/03
VBI Vaccines Sells Rights to Hepatitis B Vaccine to Brii Biosciences	14/02
Brii Biosciences to Buy Rights to Hepatitis B Vaccine from VBI	14/02
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies	14/02
Brii Biosciences Hires Chief Scientific Officer	04/01
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer	03/01
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer	03/01
Brii Biosciences Presents Hepatitis B Treatment Data at US Liver Disease Conference	14/11
PBrii Biosciences Limited Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting 2023	14/11
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 in Combination with PEG-IFN for the Treatment of Chronic Hepatitis B	07/09/23
Brii Biosciences’ Study Into Therapeutic Vaccine for Chronic Hepatitis B Patients Shows Safety, Tolerability	06/09/23
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B	06/09/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Brii Biosciences Limited

Actions

2137

KYG1645A1094

Autres langues

Filtres